What is an appropriate medication regimen with dosages for a patient with type 2 diabetes, including metformin, an SGLT2 inhibitor, a GLP‑1 receptor agonist, basal insulin, and renal function dose adjustments?

Type 2 Diabetes Medication Regimen with Dosages

For patients with type 2 diabetes, start metformin 500-850 mg once daily and titrate upward, add an SGLT2 inhibitor as first-line combination therapy, then add a long-acting GLP-1 receptor agonist if glycemic targets are not met, with basal insulin reserved for patients requiring further intensification—all with careful attention to renal function-based dose adjustments. 1

First-Line Therapy: Metformin

Metformin dosing based on renal function:

• eGFR ≥60 mL/min/1.73 m²: Start 500 mg or 850 mg once daily (immediate release) or 500 mg daily (extended release); titrate upward by 500-850 mg every 7 days to maximum dose of 2000-2550 mg daily 1
• eGFR 45-59 mL/min/1.73 m²: Continue same dose; consider dose reduction in certain clinical conditions 1
• eGFR 30-44 mL/min/1.73 m²: Reduce dose by half 1
• eGFR <30 mL/min/1.73 m²: Stop metformin; do not initiate 1

Critical monitoring: Check eGFR at least annually when ≥60 mL/min/1.73 m², every 3-6 months when <60 mL/min/1.73 m²; monitor vitamin B12 after 4 years of treatment 1

Second-Line Therapy: SGLT2 Inhibitor

SGLT2 inhibitors should be added to metformin as the preferred second agent because they reduce all-cause mortality, major adverse cardiovascular events, chronic kidney disease progression, and heart failure hospitalizations 1. Prioritize SGLT2 inhibitors in patients with heart failure or CKD 1.

Common SGLT2 inhibitor options (no renal dose adjustment needed for cardiovascular/renal benefits):

• Empagliflozin: 10 mg once daily, may increase to 25 mg once daily
• Dapagliflozin: 10 mg once daily
• Canagliflozin: 100 mg once daily, may increase to 300 mg once daily if eGFR ≥60 mL/min/1.73 m²

Initiate when eGFR ≥20 mL/min/1.73 m² and continue until dialysis or transplantation even if eGFR falls below 20 mL/min/1.73 m² 2. Starting with an SGLT2 inhibitor before a GLP-1 agonist provides superior long-term kidney function preservation 3.

Third-Line Therapy: GLP-1 Receptor Agonist

Add a long-acting GLP-1 receptor agonist if glycemic targets are not met with metformin plus SGLT2 inhibitor, or if SGLT2 inhibitors cannot be used 1. GLP-1 agonists reduce all-cause mortality, major adverse cardiovascular events, and stroke 1. Prioritize in patients with high stroke risk or when weight loss is an important goal 1.

Long-acting GLP-1 receptor agonist dosing (prioritize agents with cardiovascular benefits):

• Semaglutide (subcutaneous): Start 0.25 mg once weekly for 4 weeks, increase to 0.5 mg once weekly; may increase to 1 mg once weekly after 4 weeks if needed; maximum 2 mg once weekly. No renal dose adjustment required 1

• Dulaglutide: Start 0.75 mg once weekly, may increase to 1.5 mg once weekly; maximum 4.5 mg once weekly. Use with eGFR >15 mL/min/1.73 m²; no dose adjustment needed 1

• Liraglutide: Start 0.6 mg once daily for 1 week, increase to 1.2 mg once daily; may increase to 1.8 mg once daily after 1 week if needed. No dose adjustment; limited data in severe CKD 1

Start with low doses and titrate slowly to minimize gastrointestinal side effects 1. Do not combine with DPP-4 inhibitors 1.

Fourth-Line Therapy: Basal Insulin

Add basal insulin if glycemic targets remain unmet despite triple therapy with metformin, SGLT2 inhibitor, and GLP-1 agonist 1. Insulin is appropriate for all levels of renal function, including dialysis patients 1.

Basal insulin options:

• Insulin glargine U-100: Start 10 units once daily or 0.1-0.2 units/kg once daily; titrate by 2-4 units every 3 days based on fasting glucose
• Insulin degludec: Start 10 units once daily; titrate by 2-4 units every 3 days based on fasting glucose
• Insulin detemir: Start 10 units once daily or twice daily; titrate by 2-4 units every 3 days

When adding insulin, reduce or discontinue sulfonylureas to avoid severe hypoglycemia 1. The hypoglycemia risk with GLP-1 agonists plus insulin is generally low, but monitor closely 1.

Critical Treatment Sequencing

The order matters: Initiating SGLT2 inhibitors before GLP-1 agonists provides better long-term kidney function preservation compared to the reverse sequence 3. This supports SGLT2 inhibitors as foundational therapy even when subsequent GLP-1 agonist intensification is required 3.

Key Monitoring and Adjustments

• Target HbA1c 7-8% in most adults; deintensify if HbA1c <6.5% 1
• Self-monitoring of blood glucose may be unnecessary with metformin plus SGLT2 inhibitor or GLP-1 agonist combinations 1
• Avoid DPP-4 inhibitors as add-on therapy—they do not reduce morbidity or mortality 1
• Sulfonylureas and long-acting insulins are inferior to SGLT2 inhibitors and GLP-1 agonists for reducing mortality and morbidity 1

Common Pitfalls to Avoid

Do not delay SGLT2 inhibitor initiation waiting for metformin failure—add it early, especially in patients with heart failure or CKD 1. Do not stop SGLT2 inhibitors when eGFR falls below 20 mL/min/1.73 m²—continue until dialysis for persistent cardiovascular and kidney benefits 2. Do not combine GLP-1 agonists with DPP-4 inhibitors—this provides no additional benefit 1.